Acrivon Therapeutics Reports A 50% Confirmed Overall Response Rate Observed With ACR-368 In Oncosignature-Positive Gynecological Cancers; Initial Clinical Validation Of AP3 Patient Selection Platform, Demonstrated Ability To Prospectively Predict ACR-368 RECIST Responders
Acrivon Therapeutics 報告稱,在 Oncosignature 陽性婦科癌中觀察到 ACR-368 的總體緩解率爲 50%;AP3 患者選擇平台的初步臨床驗證,顯示出前瞻性預測 ACR-368 RECIST 反應者的能力